SALT LAKE CITY – USANA Health Sciences, Inc. (NYSE:), a company specializing in cellular nutrition with a market capitalization of $655 million and impressive gross profit margins of 81%, has appointed Dr. Kathryn Armstrong as its new chief scientific officer. According to InvestingPro analysis, USANA maintains strong financial health with a “GOOD” overall rating. With 17 years of scientific expertise, Armstrong transitions from her role as executive vice president of research and development, a position she has held since July 2024.
Armstrong succeeds Dr. Rob Sinnott, who retired at the end of 2024 but will continue to contribute as a senior scientific fellow. Armstrong’s academic credentials include a B.S. in Chemistry from Loyola University Chicago and a Ph.D. in Biochemistry from the University of Notre Dame. Her professional journey began at Whirlpool Corporation (NYSE:), followed by roles at BISSELL Homecare, Inc., and nearly nine years at Amway in various leadership positions.
Jim Brown, CEO and president of USANA, expressed confidence in Armstrong’s capabilities to lead the company’s scientific initiatives. He also extended gratitude to Dr. Sinnott for his significant contributions to USANA’s growth and scientific advancements.
In her new role, Armstrong will oversee a team of around 150 professionals across multiple departments, including product development, regulatory affairs, and quality control. She aims to uphold the vision of USANA’s founder, Dr. Myron Wentz, focusing on scientifically-supported nutritional products and empowering individuals in their wellness journeys.
USANA, recognized for its high-quality nutritional products and skincare lines, has established itself as a trusted brand over the past three decades. The company’s commitment to science and innovation continues to be a key factor in its market position. Trading at a P/E ratio of 12, InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US equities.
This leadership change is part of USANA’s ongoing efforts to reinforce its scientific research and development capabilities. The information about Dr. Kathryn Armstrong’s appointment is based on a press release statement from USANA. For investors seeking deeper insights into USANA’s financial health and growth prospects, InvestingPro offers 12 additional key investment tips and comprehensive financial metrics.
In other recent news, USANA Health Sciences, Inc. has acquired a 78.8% controlling interest in Hiya Health Products, a firm specializing in children’s wellness products. The $205 million cash transaction is expected to contribute positively to USANA’s 2025 adjusted EBITDA. Hiya reported net sales of $103 million, net income of $19 million, and adjusted EBITDA of $22 million as of September 30, 2024. The acquisition aligns with USANA’s strategy to diversify growth and distribution channels, potentially enhancing profitability. Hiya’s founders, Darren Litt and Adam Gillman, will continue to lead the company, leveraging USANA’s international expertise to expand product reach.
In other recent developments, USANA reported a challenging third quarter, with net sales falling below expectations due to a difficult operating environment in China. The company plans to increase promotional activities in the fourth quarter. New products were also launched, including Celavive Resurfacing Serum and Whey Protein Isolate in North America. Despite increased spending on incentives and promotional activities anticipated to affect Q4 margins, the company remains cautiously optimistic about the impact of Chinese government stimulus on consumer spending.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
